Osteonecrosis of the Jaw After Osteoporosis Therapy With Denosumab Following Long-term Bisphosphonate Therapy
Abstract Osteonecrosis of the jaw (ONJ) is a common and potentially severe complication of antiresorptive therapy for bone metastases. However, its occurrence in patients treated for osteoporosis is rare. Although poor oral hygiene and invasive dental procedures have been identified as potential tri...
Gespeichert in:
| Veröffentlicht in: | Mayo Clinic proceedings 2013-04, Vol.88 (4), p.418-419 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 419 |
|---|---|
| container_issue | 4 |
| container_start_page | 418 |
| container_title | Mayo Clinic proceedings |
| container_volume | 88 |
| creator | Rachner, Tilman D., MD Platzbecker, Uwe, MD Felsenberg, Dieter, MD Hofbauer, Lorenz C., MD |
| description | Abstract Osteonecrosis of the jaw (ONJ) is a common and potentially severe complication of antiresorptive therapy for bone metastases. However, its occurrence in patients treated for osteoporosis is rare. Although poor oral hygiene and invasive dental procedures have been identified as potential triggers, little is known about the role of other systemic risk factors. We describe a patient who developed ONJ after her first treatment with denosumab, a monoclonal antibody against receptor activator of NF-κB ligand. This patient had several comorbidities that prompted us to assess the German ONJ registry for the incidence of comorbidities in patients with ONJ. In summary, almost half of the patients (35 of 86 [41%]) had 1 or more risk factors thought to increase the risk of ONJ. In conclusion, comorbidities or comedications may increase the susceptibility of developing ONJ during osteoporosis therapy. |
| doi_str_mv | 10.1016/j.mayocp.2013.01.002 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1322732451</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A328422099</galeid><els_id>S002561961300030X</els_id><sourcerecordid>A328422099</sourcerecordid><originalsourceid>FETCH-LOGICAL-c561t-64f2ce34ff835801380c98f7eaaf875da8f57294dbdbe1c3f8e4ea410c0d10053</originalsourceid><addsrcrecordid>eNqFkttu1DAQhiNERZfCGyAUCQlxk-BTTjdIS6G01Uq9oAjuLK8z3nhJ7NR2qPbtcUjLoTfIsiyNv388nn-S5AVGOUa4fLvPB3GwcswJwjRHOEeIPEpWuGEkKwpWPk5WMVJkJW7K4-Sp93uEUNU07ElyTGjB5iSrZLjyAawB6azXPrUqDR2kl-I2XasALv11Pdrl9roDJ8ZD-lWHLv0AxvppENv0zPa9vdVml26s2WVRNqTvtR87O28jAtwrnyVHSvQent-dJ8mXs4_Xp-fZ5urTxel6k8mixCErmSISKFOqpkUdv1cj2dSqAiFUXRWtqFVRkYa123YLWFJVAwMRfyRRixEq6EnyZsk7OnszgQ980F5C3wsDdvIcU0IqSliBI_rqAbq3kzOxupmqKWmqsopUvlA70QPXRtnghIyrhUHL2D-lY3wdBYwQ1DRR8PovQQeiD523_RS0Nf5fkC3g7IB3oPjo9CDcgWPEZ4_4ni9G89lojjCPtkbZy7uyp-0A7W_RvbMReLcAEPv8Q4PjXmowElrtQAbeWv2_Fx4mkL02Wor-OxzA_-kS94Qj_nketnnWMI1zRtE3-hNhD8_L</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1328329767</pqid></control><display><type>article</type><title>Osteonecrosis of the Jaw After Osteoporosis Therapy With Denosumab Following Long-term Bisphosphonate Therapy</title><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Rachner, Tilman D., MD ; Platzbecker, Uwe, MD ; Felsenberg, Dieter, MD ; Hofbauer, Lorenz C., MD</creator><creatorcontrib>Rachner, Tilman D., MD ; Platzbecker, Uwe, MD ; Felsenberg, Dieter, MD ; Hofbauer, Lorenz C., MD</creatorcontrib><description>Abstract Osteonecrosis of the jaw (ONJ) is a common and potentially severe complication of antiresorptive therapy for bone metastases. However, its occurrence in patients treated for osteoporosis is rare. Although poor oral hygiene and invasive dental procedures have been identified as potential triggers, little is known about the role of other systemic risk factors. We describe a patient who developed ONJ after her first treatment with denosumab, a monoclonal antibody against receptor activator of NF-κB ligand. This patient had several comorbidities that prompted us to assess the German ONJ registry for the incidence of comorbidities in patients with ONJ. In summary, almost half of the patients (35 of 86 [41%]) had 1 or more risk factors thought to increase the risk of ONJ. In conclusion, comorbidities or comedications may increase the susceptibility of developing ONJ during osteoporosis therapy.</description><identifier>ISSN: 0025-6196</identifier><identifier>EISSN: 1942-5546</identifier><identifier>DOI: 10.1016/j.mayocp.2013.01.002</identifier><identifier>PMID: 23541016</identifier><identifier>CODEN: MACPAJ</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Aged ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Bone Density Conservation Agents - adverse effects ; Bone Density Conservation Agents - therapeutic use ; Bones ; Complications and side effects ; Denosumab ; Diphosphonates - therapeutic use ; Female ; Humans ; Internal Medicine ; Jaw Diseases - chemically induced ; Jaw Diseases - diagnosis ; Necrosis ; Osteonecrosis - chemically induced ; Osteonecrosis - diagnosis ; Osteoporosis, Postmenopausal - drug therapy</subject><ispartof>Mayo Clinic proceedings, 2013-04, Vol.88 (4), p.418-419</ispartof><rights>Mayo Foundation for Medical Education and Research</rights><rights>2013 Mayo Foundation for Medical Education and Research</rights><rights>Copyright © 2013 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</rights><rights>COPYRIGHT 2013 Elsevier, Inc.</rights><rights>Copyright Mayo Foundation for Medical Education and Research Apr 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c561t-64f2ce34ff835801380c98f7eaaf875da8f57294dbdbe1c3f8e4ea410c0d10053</citedby><cites>FETCH-LOGICAL-c561t-64f2ce34ff835801380c98f7eaaf875da8f57294dbdbe1c3f8e4ea410c0d10053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1328329767?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23541016$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rachner, Tilman D., MD</creatorcontrib><creatorcontrib>Platzbecker, Uwe, MD</creatorcontrib><creatorcontrib>Felsenberg, Dieter, MD</creatorcontrib><creatorcontrib>Hofbauer, Lorenz C., MD</creatorcontrib><title>Osteonecrosis of the Jaw After Osteoporosis Therapy With Denosumab Following Long-term Bisphosphonate Therapy</title><title>Mayo Clinic proceedings</title><addtitle>Mayo Clin Proc</addtitle><description>Abstract Osteonecrosis of the jaw (ONJ) is a common and potentially severe complication of antiresorptive therapy for bone metastases. However, its occurrence in patients treated for osteoporosis is rare. Although poor oral hygiene and invasive dental procedures have been identified as potential triggers, little is known about the role of other systemic risk factors. We describe a patient who developed ONJ after her first treatment with denosumab, a monoclonal antibody against receptor activator of NF-κB ligand. This patient had several comorbidities that prompted us to assess the German ONJ registry for the incidence of comorbidities in patients with ONJ. In summary, almost half of the patients (35 of 86 [41%]) had 1 or more risk factors thought to increase the risk of ONJ. In conclusion, comorbidities or comedications may increase the susceptibility of developing ONJ during osteoporosis therapy.</description><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bones</subject><subject>Complications and side effects</subject><subject>Denosumab</subject><subject>Diphosphonates - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Jaw Diseases - chemically induced</subject><subject>Jaw Diseases - diagnosis</subject><subject>Necrosis</subject><subject>Osteonecrosis - chemically induced</subject><subject>Osteonecrosis - diagnosis</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><issn>0025-6196</issn><issn>1942-5546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkttu1DAQhiNERZfCGyAUCQlxk-BTTjdIS6G01Uq9oAjuLK8z3nhJ7NR2qPbtcUjLoTfIsiyNv388nn-S5AVGOUa4fLvPB3GwcswJwjRHOEeIPEpWuGEkKwpWPk5WMVJkJW7K4-Sp93uEUNU07ElyTGjB5iSrZLjyAawB6azXPrUqDR2kl-I2XasALv11Pdrl9roDJ8ZD-lWHLv0AxvppENv0zPa9vdVml26s2WVRNqTvtR87O28jAtwrnyVHSvQent-dJ8mXs4_Xp-fZ5urTxel6k8mixCErmSISKFOqpkUdv1cj2dSqAiFUXRWtqFVRkYa123YLWFJVAwMRfyRRixEq6EnyZsk7OnszgQ980F5C3wsDdvIcU0IqSliBI_rqAbq3kzOxupmqKWmqsopUvlA70QPXRtnghIyrhUHL2D-lY3wdBYwQ1DRR8PovQQeiD523_RS0Nf5fkC3g7IB3oPjo9CDcgWPEZ4_4ni9G89lojjCPtkbZy7uyp-0A7W_RvbMReLcAEPv8Q4PjXmowElrtQAbeWv2_Fx4mkL02Wor-OxzA_-kS94Qj_nketnnWMI1zRtE3-hNhD8_L</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>Rachner, Tilman D., MD</creator><creator>Platzbecker, Uwe, MD</creator><creator>Felsenberg, Dieter, MD</creator><creator>Hofbauer, Lorenz C., MD</creator><general>Elsevier Inc</general><general>Elsevier, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4U-</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20130401</creationdate><title>Osteonecrosis of the Jaw After Osteoporosis Therapy With Denosumab Following Long-term Bisphosphonate Therapy</title><author>Rachner, Tilman D., MD ; Platzbecker, Uwe, MD ; Felsenberg, Dieter, MD ; Hofbauer, Lorenz C., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c561t-64f2ce34ff835801380c98f7eaaf875da8f57294dbdbe1c3f8e4ea410c0d10053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bones</topic><topic>Complications and side effects</topic><topic>Denosumab</topic><topic>Diphosphonates - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Jaw Diseases - chemically induced</topic><topic>Jaw Diseases - diagnosis</topic><topic>Necrosis</topic><topic>Osteonecrosis - chemically induced</topic><topic>Osteonecrosis - diagnosis</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rachner, Tilman D., MD</creatorcontrib><creatorcontrib>Platzbecker, Uwe, MD</creatorcontrib><creatorcontrib>Felsenberg, Dieter, MD</creatorcontrib><creatorcontrib>Hofbauer, Lorenz C., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Mayo Clinic proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rachner, Tilman D., MD</au><au>Platzbecker, Uwe, MD</au><au>Felsenberg, Dieter, MD</au><au>Hofbauer, Lorenz C., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Osteonecrosis of the Jaw After Osteoporosis Therapy With Denosumab Following Long-term Bisphosphonate Therapy</atitle><jtitle>Mayo Clinic proceedings</jtitle><addtitle>Mayo Clin Proc</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>88</volume><issue>4</issue><spage>418</spage><epage>419</epage><pages>418-419</pages><issn>0025-6196</issn><eissn>1942-5546</eissn><coden>MACPAJ</coden><abstract>Abstract Osteonecrosis of the jaw (ONJ) is a common and potentially severe complication of antiresorptive therapy for bone metastases. However, its occurrence in patients treated for osteoporosis is rare. Although poor oral hygiene and invasive dental procedures have been identified as potential triggers, little is known about the role of other systemic risk factors. We describe a patient who developed ONJ after her first treatment with denosumab, a monoclonal antibody against receptor activator of NF-κB ligand. This patient had several comorbidities that prompted us to assess the German ONJ registry for the incidence of comorbidities in patients with ONJ. In summary, almost half of the patients (35 of 86 [41%]) had 1 or more risk factors thought to increase the risk of ONJ. In conclusion, comorbidities or comedications may increase the susceptibility of developing ONJ during osteoporosis therapy.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>23541016</pmid><doi>10.1016/j.mayocp.2013.01.002</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-6196 |
| ispartof | Mayo Clinic proceedings, 2013-04, Vol.88 (4), p.418-419 |
| issn | 0025-6196 1942-5546 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1322732451 |
| source | MEDLINE; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | Aged Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Bones Complications and side effects Denosumab Diphosphonates - therapeutic use Female Humans Internal Medicine Jaw Diseases - chemically induced Jaw Diseases - diagnosis Necrosis Osteonecrosis - chemically induced Osteonecrosis - diagnosis Osteoporosis, Postmenopausal - drug therapy |
| title | Osteonecrosis of the Jaw After Osteoporosis Therapy With Denosumab Following Long-term Bisphosphonate Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T03%3A57%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Osteonecrosis%20of%20the%20Jaw%20After%20Osteoporosis%20Therapy%20With%20Denosumab%20Following%20Long-term%20Bisphosphonate%20Therapy&rft.jtitle=Mayo%20Clinic%20proceedings&rft.au=Rachner,%20Tilman%20D.,%20MD&rft.date=2013-04-01&rft.volume=88&rft.issue=4&rft.spage=418&rft.epage=419&rft.pages=418-419&rft.issn=0025-6196&rft.eissn=1942-5546&rft.coden=MACPAJ&rft_id=info:doi/10.1016/j.mayocp.2013.01.002&rft_dat=%3Cgale_proqu%3EA328422099%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1328329767&rft_id=info:pmid/23541016&rft_galeid=A328422099&rft_els_id=S002561961300030X&rfr_iscdi=true |